1. An antibody fragment against human delta-like ligand-4 for inhibition of cell proliferation and neovascularization.
- Author
-
Baharlou R, Tajik N, Behdani M, Shokrgozar MA, Tavana V, Kazemi-Lomedasht F, Faraji F, and Habibi-Anbouhi M
- Subjects
- Animals, Apoptosis drug effects, Cell Line, Tumor, Chick Embryo, Chorioallantoic Membrane drug effects, HEK293 Cells, Humans, Angiogenesis Inhibitors pharmacology, Antibodies, Monoclonal pharmacology, Cell Proliferation drug effects, Immunoglobulin Fragments pharmacology, Intracellular Signaling Peptides and Proteins immunology, Membrane Proteins immunology, Neovascularization, Pathologic drug therapy
- Abstract
Objectives: Angiogenesis targeting is an attractive approach for cancer treatment. Delta-like ligand 4 (DLL4) plays a pivotal role in neovascular development and its inhibitors have recently entered clinical trials for solid tumors. The aim of this study was to evaluate the possibilities of using anti-DLL4 antibody fragment as an angiogenesis maturation inhibitor., Materials and Methods: In this study, a DLL4-specific Nanobody, named 3Nb3, was selected and assessed by western blotting and internalization assays. Functional assessments included MTT, apoptosis, and chicken chorioallantoic membrane (CAM) assays., Results: Based on the results, 3Nb3 specifically binds to DLL4 and internalizes into MKN cell. Furthermore, 3Nb3 significantly inhibited the proliferation of cells and also neovascularization in the CAM., Conclusions: These data demonstrated the potential of Nanobody for application in targeting DLL4. Our findings may provide a basis for the development of novel therapeutic techniques to inhibit growth and neovascularization of tumors.
- Published
- 2018
- Full Text
- View/download PDF